Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma

29 Aug 2025

Abstract excerpt

Programmed death ligand 1 (PD-L1) is a protein expressed in hepatocellular carcinoma (HCC) that drives immune evasion by binding to programmed death receptor 1 (PD-1) on activated T cells. Understanding PD-L1 regulation is essential to understand the immunosuppressive microenvironment for antitumor immunity. We screened ribonucleic acid (RNA)-binding motif proteins (RBMs). RBM30 can enhance PD-L1 expression in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40883414
DOI: 10.1038/s41388-025-03550-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinomaPMID 40883414Read ↗

RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translationSemantic proximity Read ↗

EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-βSemantic proximity Read ↗

A systematic pan-cancer analysis identifies TRIM28 as an immunological and prognostic predictor and involved in immunotherapy resistanceSemantic proximity Read ↗

M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

The current status and future of PD-L1 in liver cancerSemantic proximity Read ↗

MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer typesSemantic proximity Read ↗

The prognostic significance of FoxM1 and its immune regulatory function in Liver Hepatocellular CarcinomaSemantic proximity Read ↗

TRIM31: A molecule with a dual role in cancerSemantic proximity Read ↗

N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancerSemantic proximity Read ↗

m 6 A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinomaSemantic proximity Read ↗

Dual function of DOT1L suppresses tumor intrinsic immunogenicity in hepatocellular carcinomaSemantic proximity Read ↗

The 3’ non-coding sequence negatively regulates PD-L1 expression and its regulators are systematically identified in pan-cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.